BioNano Genomics Inc vs Intel Corp — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Intel Corp trades at $101.83 (market cap $492.85B). The key difference: Intel Corp is far larger — about 36079.8× BioNano Genomics Inc's market cap, and Intel Corp pays a 2.24% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | INTC | |
|---|---|---|
Market Cap | $13.66M | $492.85B |
Sector | Health | Technology |
52-Week High | $4.92 | $140.94 |
52-Week Low | $1.06 | $21.81 |
Enterprise Value | $16.26M | $513.66B |
Volume | — | 43,552,012 |
Dividend Yield | — | 2.24% |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Intel (INTC) trades at $100.51, up 3.07% today, with a bullish technical signal and recent earnings beats. Revenue grew 25% year-over-year in Q2 2026, driven by data center and AI segments, though net income margins remain negative. The company recently upsized a stock offering to $20 billion to fund AI and manufacturing investments, causing some investor concern over dilution but supporting long-term growth initiatives.
Outlook is mixed: strong revenue growth and analyst consensus price target of $116.67 suggest upside, but high valuation ratios, negative profitability, and execution risks in the capital-intensive foundry business pose challenges. Investor sentiment is cautiously optimistic amid the AI-driven turnaround narrative.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →